PHS
NVAX icon

PFM Health Sciences’s Novavax NVAX Stock Holding History

PFM Health Sciences’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-88,663
Closed -$12.7M – 74
2021
Q4 		$12.7M Sell
88,663
-108,545
-55% -$18.7M 0.43% 52
2021
Q3 		$40.9M Buy
197,208
+48,104
+32% +$10.6M 1.2% 38
2021
Q2 		$31.7M Sell
149,104
-51,641
-26% -$9.46M 0.99% 39
2021
Q1 		$36.4M Sell
200,745
-15,163
-7% -$3.02M 1.11% 32
2020
Q4 		$24.1M Buy
+215,908
New +$22.9M 0.85% 46

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PFM Health Sciences's NVAX Position: Q1 2022 in Review

PFM Health Sciences sold out of Novavax (NVAX) in Q1 2022, closing a stake of 88,663 shares — an estimated $12.7M sold.

PFM Health Sciences first reported a position in NVAX in Q4 2020 and held it in 5 quarters. The position peaked at $40.9M in Q3 2021. 381 funds tracked by Wall St. Rank hold NVAX as of Q1 2022.

  • PFM Health Sciences reported no remaining Novavax position as of Q1 2022 after selling out during the quarter.
  • PFM Health Sciences sold 88,663 Novavax shares in Q1 2022, an estimated $12.7M.
  • PFM Health Sciences first reported a position in Novavax in Q4 2020 and held it in 5 quarters.
  • PFM Health Sciences's Novavax position peaked at $40.9M in Q3 2021.
  • 381 funds tracked by Wall St. Rank held Novavax as of Q1 2022.

Based on PFM Health Sciences's 13F filing for Q1 2022, filed 16 May 2022.